In this regard, it is of interest that we found an effect of IL-9 and anti-IL-9 treatment on mast cells, given recent evidence that mast cells may play a pathogenic role in psoriasis by augmenting VEGF release and thereby increasing inflammation via functional interactions with substance P and IL-33 [43]. The gene discussed is IL33; the disease is psoriasis.